Original Research
Published on 24 Jan 2025
Cost-effectiveness analysis of gumarontinib versus savolitinib for the treatment of advanced or metastatic NSCLC with MET exon 14 skipping mutations in China using partitioned survival model
in Drugs Outcomes Research and Policies
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1400422
- 3,407 views
- 1 citation


